COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,386 Articles (22,816 medRxiv, 8,570 bioRxiv)

Most recent first Previous |  Page 1111: Articles 11101-11110  | Next

Post-Translational Modifications Optimize the Ability of SARS-CoV-2 Spike for Effective Interaction with Host Cell Receptors
Kapoor, K., Chen, T., Tajkhorshid, E.
10.1101/2021.12.02.470852 — Posted: 2021-12-03
Omicron and Delta Variant of SARS-CoV-2: A Comparative Computational Study of Spike protein
Kumar, S., Thambiraja, T. S., Karuppanan, K., Subramaniam, G.
10.1101/2021.12.02.470946 — Posted: 2021-12-03 Discussion: Onsite
Online Phylogenetics using Parsimony Produces Slightly Better Trees and is Dramatically More Efficient for Large SARS-CoV-2 Phylogenies than de novo and Maximum-Likelihood Approaches
Thornlow, B., Ye, C., De Maio, N., McBroome, J., Hinrichs, A. S., Lanfear, R., Turakhia, Y., Corbett-Detig, R.
10.1101/2021.12.02.471004 — Posted: 2021-12-03 Discussion: Onsite
Unconventional secretion of unglycosylated ORF8 is critical for the cytokine storm during SARS-CoV-2 infection
Lin, X., Fu, B., Xiong, Y., Xing, N., Xue, W., Guo, D., Y. Zaky, M., Pavani, K. C., Kunec, D., Trimpert, J., Wu, H.
10.1101/2021.12.03.471057 — Posted: 2021-12-03
Systems immune profiling of variant-specific vaccination against SARS-CoV-2
Peng, L., Park, J., Fang, Z., Zhou, X., Dong, M., Xiong, Q., Lin, C., Chen, S.
10.1101/2021.12.02.471028 — Posted: 2021-12-03
Secreted ORF8 is a pathogenic cause of severe Covid-19 and potentially targetable with select NLRP3 inhibitors
Wu, X., Manske, M. K., Ruan, G., Nowakowski, K. E., Abeykoon, J. P., Tang, X., Yu, Y., Witter, T. L., Taupin, V., Paludo, J., Ansell, S. M., Badley, A. D., Schellenberg, M., Witzig, T. E.
10.1101/2021.12.02.470978 — Posted: 2021-12-03
Drug repurposing screening identified tropifexor as a SARS-CoV-2 papain-like protease inhibitor
Ma, C., Wang, Y., Choza, J., Wang, J.
10.1101/2021.12.02.471030 — Posted: 2021-12-03
SARS-CoV-2 wildlife surveillance in Ontario and Quebec, Canada
Greenhorn, J. E., Kotwa, J. D., Bowman, J., Bruce, L., Buchanan, T., Buck, P. A., Dibernardo, A., Flockhart, L., Gagnier, M., Hou, A., Jardine, C. M., Lair, S., Lindsay, L. R., Masse, A., Muchaal, P. K., Nituch, L. A., Sotto, A., Stevens, B., Yip, L., Mubareka, S.
10.1101/2021.12.02.470924 — Posted: 2021-12-03
Investigating the human host - ssRNA virus interaction landscape using the SMEAGOL toolbox
Lal, A., Ferrarini, M. G., Gruber, A. J.
10.1101/2021.12.02.470930 — Posted: 2021-12-03
Macaque-human differences in SARS-CoV-2 Spike antibody response elicited by vaccination or infection
Willcox, A., Sung, K., Garrett, M. E., Galloway, J. G., OConnor, M. A., Erasmus, J. H., Logue, J. K., Hawman, D. W., Chu, H. Y., Hasenkrug, K. J., Fuller, D. H., Matsen, F. A., Overbaugh, J.
10.1101/2021.12.01.470697 — Posted: 2021-12-03

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).